Evidence Library
Research & Clinical Evidence Center
The studies and guidelines summarized here are widely cited in metabolic medicine. Summaries are educational and intentionally avoid treatment recommendations for individual patients.
Foundational guidelines
- ADA — Standards of Care in Diabetes: annual evidence-based guidance from the American Diabetes Association covering screening, diagnosis, glycemic targets, complications, and therapy.
- AACE — Obesity Algorithm: complications-centric framework from the American Association of Clinical Endocrinology for staging and managing obesity.
- ACC/AHA — Cardiovascular Risk Guidelines: risk assessment, lipid management, and hypertension thresholds.
- AASLD — MASLD/MASH Guidance: diagnostic and management framework for steatotic liver disease.
Landmark trials
Diabetes Prevention Program (DPP)
Demonstrated that an intensive lifestyle intervention reduced the incidence of type 2 diabetes by 58% over an average of 2.8 years in adults with prediabetes; metformin reduced incidence by 31%.1
Look AHEAD
Showed that intensive lifestyle intervention produced sustained weight loss and improvements in many cardiometabolic markers, though it did not reduce the primary composite cardiovascular endpoint over the trial period.
STEP and SURMOUNT
Phase 3 programs evaluating semaglutide (STEP) and tirzepatide (SURMOUNT) demonstrated clinically meaningful, placebo-adjusted weight reduction in adults with overweight or obesity.2
SELECT
Among adults with overweight or obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg weekly reduced major adverse cardiovascular events compared with placebo.3
Swedish Obese Subjects (SOS)
A long-running prospective cohort comparing bariatric surgery with usual care; showed long-term reductions in cardiovascular events, incident diabetes, and overall mortality in surgical patients.
DiRECT
Primary-care-led structured weight management produced remission of type 2 diabetes in a substantial fraction of participants at 12 and 24 months, with remission strongly related to weight loss magnitude.
Emerging directions
Active areas include next-generation incretin combinations (e.g., triple agonists), oral GLP-1 analogues, MASH-directed pharmacotherapy, precision-medicine approaches based on subtype phenotyping, and refinements in endoscopic and surgical technique. Findings should be interpreted with caution until replicated in long-term trials.